Results from the Phase 3 part of AMETHYST are expected in the first half of 2027; in January 2026 the FDA granted ...
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced new data evaluating the efficacy and safety of POMBILITI ® ...
In 2025, the AAP updated its guidance to recommend exome or genome sequencing as a first-tier test for children with global ...
Capitalizing on space’s microgravity, the United Therapeutics–partnered Varda Space Industries aims to make medicines with ...
Includes worldwide license to ABO2203, Abogen's mRNA-encoded CD19xCD3 T-Cell Engager . Agreement also gives Novartis ...
Bristol Myers Squibb will soon release Phase 3 data for admilparant that could make or break Contineum Therapeutics’ rival ...
Amid rising industry concerns about U.S. competitiveness with China, the Trump administration is rolling out four ARPA-H ...
Despite meeting the primary endpoints in a Phase 3 trial, shares of Zealand Pharma dropped in premarket trading Thursday as ...
Sanofi and Regeneron have had a long and “sometimes contentious” partnership, BMO Capital Markets noted, as the companies ...
CaseBioscience® today announced its participation in a multidisciplinary team led by Likarda that has been awarded up to $7.3 ...
Merck has revealed detailed data for tulisokibart from a mid-stage trial in hidradenitis suppurativa that analysts say could ...
Balstilimab is a novel, fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 (programmed cell death protein ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results